| 000 | 01453 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516165502.0 | ||
| 264 | 0 | _c20140512 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1517/14656566.2013.832202 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPosadas, Edwin M | |
| 245 | 0 | 0 |
_aTargeting angiogenesis in renal cell carcinoma. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cNov 2013 |
||
| 300 |
_a2221-36 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aFibroblast Growth Factors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-met _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 700 | 1 | _aLimvorasak, Suwicha | |
| 700 | 1 | _aSharma, Shaleekha | |
| 700 | 1 | _aFiglin, Robert A | |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 14 _gno. 16 _gp. 2221-36 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14656566.2013.832202 _zAvailable from publisher's website |
| 999 |
_c23040749 _d23040749 |
||